SDR-PEP Rifampicin — Competitive Intelligence Brief

SDR-PEP Rifampicin (SDR-PEP Rifampicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Infectious Disease.

phase 3 Rifamycin antibiotic Bacterial RNA polymerase (mycobacterial) Infectious Disease Small molecule

Target snapshot

SDR-PEP Rifampicin (SDR-PEP Rifampicin) — Institute of Tropical Medicine, Belgium. SDR-PEP Rifampicin is a sustained-release formulation of rifampicin that inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SDR-PEP Rifampicin TARGET	SDR-PEP Rifampicin	Institute of Tropical Medicine, Belgium	phase 3	Rifamycin antibiotic	Bacterial RNA polymerase (mycobacterial)
Rifamycin-containing regimen	Rifamycin-containing regimen	National Taiwan University Hospital	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifaximin (drug)	Rifaximin (drug)	Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifampicin (R)	Rifampicin (R)	University College, London	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin (RIF)	Rifampicin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Rifampin (RIF)	Rifampin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class